Swedish aerosol research instrument maker Inhalation Sciences (ISAB) says that the company intends to expand its presence in the US in 2021 and has signed agreements with lead generation company Cience and with CRO consultant Coelus Bio to help it achieve that goal. In October 2020, ISAB announced that it had been granted a US patent for its PreciseInhale laboratory aerosol dosing system.
ISAB CEO Manoush Masarrat commented, “The US stands for almost 50% of the global inhalation market and its respiratory research sector is one of the most dynamic and robust in the world. We’ve always had great links with the US, scientifically, and commercially, now we want to strengthen those links. The new message we’re sending to colleagues in CROs and pharma companies in the US is loud and clear – our research technology and services can help you de-risk your clinical programs and find the shortest route to the right drug candidate.”
Chief Commercial Officer Paolo Raffaelli said, “While we are improving our digital reach and preparing for the future, we are also investing in outbound marketing partnerships to strengthen our brand in the US, a key market for Inhalation Sciences. Cience is a worldwide leader in B2B lead generation. Coelus and its principal Matthew Reed, a former VP of Nonclinical Development at the prestigious Lovelace Respiratory Research Institute, bring over 20 years of experience in inhaled drug development and a wealth of pharma contacts to our team. I am confident these activities will put Inhalation Sciences on the map of the US inhalation drug development scientific community.”
Read the Inhalation Sciences press release.
